©1996-2019. All Rights Reserved. Online Journal of Bioinformatics . You may not store these pages in any form except for your own personal use. All other usage or distribute on is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to OJB publications. This article may be copied once but may not be, reproduced or re-transmitted without the express permission of the editors. This journal satisfies the refereeing requirements (DEST) for the Higher Education Research Data Collection (Australia). Linking:To link to this page or any pages linking to this page you must link directly to this page only here rather than put up your own page.
OJBTM
Online Journal of Bioinformatics ©
Volume
12(1):57-65, 2011
Inhibition
of Farnesyl pyrophosphate by allosteric site drug binding
Satish
kumar(Msc), Jyoti Pathak(Msc), Asha(Msc), Rajib Bandopadhyay(PhD)
*,Department of
Biotechnology, Birla Institute of Technology, Mesra,
Ranchi-835215, Jharkhand, India
ABSTRACT
Kumar S,
Pathak J, Asha PJ, Bandopadhyay R, Inhibition of
Farnesyl pyrophosphate by allosteric site drug binding, Online J
Bioinformatics, 12(1):57-65, 2011 . Hutchinson-Gilford Progeria Syndrome
(HGPS) is caused by defective lamin A protein which remains farnesylated
after post translational modification. Zoledronate is
a potent farnesyl pyrophosphate synthase inhibitor. A total of 45 compounds
selected from the Zinc database were docked on protein FPPS through GLIDE and
their ADME score were calculated from QikProp.
The analysis suggests that ZINCID13678562, could
be used as an alternative to Zoledranate if confirmed
by In Vivo pharmacology.
Keywords: - Progeria, Zoledronate,
GLIDE, ADME, FPPS.
FULL-TEXT(SUBSCRIPTION
OR PURCHASE TITLE $25USD)